Last updated: February 19, 2026
Summary
Eli Lilly and Company (Lilly) is defending its patents for dulaglutide, the active pharmaceutical ingredient in Trulicity, against invalidity challenges filed by Teva Pharmaceuticals USA, Inc. (Teva). The dispute centers on U.S. Patent Nos. 8,703,870 and 9,089,469, which cover aspects of dulaglutide and its use. Teva argues these patents are invalid due to obviousness and lack of written description. The case is proceeding in the U.S. District Court for the District of Delaware.
What are the patents at issue in this litigation?
The litigation involves two key patents assigned to Eli Lilly and Company:
- U.S. Patent No. 8,703,870 (the '870 patent)
- U.S. Patent No. 9,089,469 (the '469 patent)
The '870 patent, titled "GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES," was filed on November 15, 2013, and issued on April 22, 2014. This patent claims pharmaceutical compositions containing dulaglutide and methods of treating type 2 diabetes.
The '469 patent, titled "GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES," was filed on May 19, 2014, and issued on July 28, 2015. This patent also claims dulaglutide, specifically its sequence, and methods of treatment.
What are Teva's primary arguments for patent invalidity?
Teva's core arguments for invalidating Lilly's patents revolve around two main legal doctrines: obviousness and lack of written description.
Is the '870 patent invalid due to obviousness?
Teva contends that the invention claimed in the '870 patent would have been obvious to a person of ordinary skill in the art at the time of filing. Teva’s argument is based on prior art that allegedly taught or suggested the claimed subject matter.
Teva specifically argues that the prior art disclosed:
- Glucagon-like peptide-1 (GLP-1) derivatives and their therapeutic potential for type 2 diabetes.
- Methods for modifying GLP-1 sequences to improve half-life and efficacy.
- The general concept of linking GLP-1 analogs to an Fc-binding protein or fragment to extend their duration of action.
Teva asserts that combining these known elements would have rendered the claimed dulaglutide obvious.
Is the '469 patent invalid due to obviousness?
Similar to its arguments for the '870 patent, Teva asserts that the '469 patent claims are also invalid due to obviousness. Teva maintains that the prior art, when considered together, would have made the claimed dulaglutide and its specific characteristics evident to a skilled artisan.
Teva's obviousness arguments for the '469 patent also point to:
- The general knowledge within the field of GLP-1 receptor agonists.
- Existing research on modifying GLP-1 for improved pharmacokinetic properties.
- The established practice of using amino acid substitutions and conjugation strategies to enhance drug half-life.
Does the '469 patent lack adequate written description?
Teva also argues that the '469 patent fails to meet the written description requirement of 35 U.S.C. § 112. This requirement mandates that the patent specification must describe the invention in sufficient detail to demonstrate that the inventor was in possession of the claimed invention at the time of filing.
Teva's position is that the '469 patent claims dulaglutide broadly, but the specification does not adequately describe this specific molecule or its properties to support such broad claims. Teva alleges that the patent describes a genus of GLP-1 derivatives but fails to provide sufficient disclosure for the specific species that is dulaglutide.
What is Lilly's defense against Teva's invalidity claims?
Eli Lilly and Company argues that its patents are valid and enforceable, asserting that Teva's challenges are without merit. Lilly defends its patents by demonstrating that the claimed inventions were not obvious and were adequately described.
How does Lilly counter the obviousness arguments?
Lilly’s defense against obviousness centers on showcasing the unexpected advantages and specific technical contributions of dulaglutide that were not taught or suggested by the prior art.
Lilly argues that:
- Unexpected Results: Dulaglutide exhibits superior properties compared to what would have been predicted by the prior art, such as enhanced efficacy, improved safety profile, or unique pharmacokinetics that were not inherent in combining known elements.
- Secondary Considerations: Evidence of commercial success, long-felt but unsolved needs in treating type 2 diabetes, and failure of others to achieve similar results with prior art approaches support the non-obviousness of dulaglutide.
- Teaching Away: Lilly may argue that the prior art actually taught away from combining specific elements in the way that leads to dulaglutide, implying that a skilled artisan would not have been motivated to make such a combination.
- Specificity of Claims: Lilly contends that its claims are directed to specific aspects of dulaglutide and its utility that are novel and non-obvious, distinguishing them from the broader teachings of the prior art.
How does Lilly address the written description requirement?
Lilly maintains that the '469 patent adequately describes dulaglutide and satisfies the written description requirement.
Lilly’s arguments include:
- Sufficient Disclosure: The patent specification provides enough detail, including amino acid sequences and functional characteristics, to demonstrate that Lilly was in possession of dulaglutide at the time of filing.
- Supporting Data: The patent may contain experimental data or examples that specifically illustrate dulaglutide and its inventive properties, thereby supporting the breadth of its claims.
- Interpreting Claims in Light of Specification: Lilly argues that the claims of the '469 patent should be read in conjunction with the detailed disclosure provided in the specification, which collectively demonstrates the inventiveness.
What is the current status of the litigation?
The litigation is ongoing in the U.S. District Court for the District of Delaware. Court filings indicate that the parties have engaged in claim construction (Markman hearings), discovery, and motion practice.
Key procedural events have included:
- Filing of the Complaint: Teva filed its complaint seeking a declaratory judgment of non-infringement and invalidity of Lilly's patents.
- Claim Construction: The court has conducted hearings to interpret the meaning of the disputed patent claims, a critical step that impacts infringement and validity analyses. The court's claim construction orders set the stage for subsequent proceedings.
- Discovery: Both parties are exchanging information and evidence through written discovery, depositions, and expert witness reports.
- Motions: The parties have filed various motions, including motions for summary judgment, which seek resolution of certain issues without a full trial.
The parties have stipulated to a stay of proceedings related to the infringement claims by Teva's proposed generic dulaglutide product until the resolution of the validity and enforceability of Lilly's asserted patents.
What are the potential outcomes of this litigation?
The outcome of this patent litigation has significant implications for both Eli Lilly and Teva, as well as the broader pharmaceutical market for type 2 diabetes treatments.
Potential outcomes include:
- Judgment of Validity and Infringement: If the court finds Lilly's patents to be valid and infringed, Teva would be blocked from launching its generic dulaglutide product, and Lilly would retain market exclusivity for Trulicity.
- Judgment of Invalidity: If the court invalidates one or both of Lilly's patents, Teva could proceed with launching its generic version of dulaglutide, potentially leading to significant price reductions and market share erosion for Trulicity.
- Partial Validity/Invalidity: It is possible that one patent is found valid and infringed, while another is found invalid, or specific claims within a patent are invalidated.
- Settlement: The parties could reach a settlement agreement, which might involve a licensing arrangement, a delayed generic entry date, or other mutually agreed-upon terms. Such settlements are common in pharmaceutical patent disputes.
What is the market significance of Trulicity?
Trulicity is a leading treatment for type 2 diabetes and a significant revenue generator for Eli Lilly. As a GLP-1 receptor agonist, it helps improve blood glucose control. The drug achieved substantial sales figures, indicating its market penetration and therapeutic value.
Key market data for Trulicity:
- 2023 Net Sales: Eli Lilly reported Trulicity net sales of approximately $5.57 billion in 2023.
- Market Position: Trulicity is one of the top-selling GLP-1 receptor agonists globally.
- Patent Expiry: The ongoing litigation directly impacts the timeline for potential generic competition, which could significantly affect Trulicity's market share and Lilly's revenue streams after patent expiry.
The expiration of patents for blockbuster drugs like Trulicity is a critical period for pharmaceutical companies. The entry of generics typically leads to a sharp decline in the brand-name drug's sales due to lower generic pricing.
Key Takeaways
- Eli Lilly is defending U.S. Patent Nos. 8,703,870 and 9,089,469 against invalidity challenges from Teva Pharmaceuticals.
- Teva's primary arguments for invalidity are obviousness and lack of written description, asserting that the prior art made dulaglutide evident and that the '469 patent insufficiently describes the claimed invention.
- Lilly counters by arguing for the unexpected advantages of dulaglutide, secondary considerations of non-obviousness, and adequate disclosure in its patent specifications.
- The litigation is proceeding in the U.S. District Court for the District of Delaware, with claim construction and discovery as key ongoing activities.
- The outcome will determine the market exclusivity for Trulicity and the potential for generic entry by Teva.
- Trulicity is a significant revenue driver for Lilly, with 2023 net sales of approximately $5.57 billion, underscoring the high stakes of this patent dispute.
Frequently Asked Questions
What is dulaglutide?
Dulaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is a once-weekly injectable medication used to improve glycemic control in adults with type 2 diabetes mellitus. It also has demonstrated benefits in reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease or multiple cardiovascular risk factors.
What is the significance of a Markman hearing in this case?
A Markman hearing is a crucial stage in patent litigation where the court determines the meaning and scope of disputed patent claims. The court's claim construction ruling establishes definitions for key terms within the patent, which then guides all subsequent analyses of infringement and validity. For Teva, a narrow construction of Lilly's claims could support invalidity or non-infringement arguments. For Lilly, a broad construction would strengthen its position against generic challenges.
What is the "written description" requirement?
The written description requirement, codified in 35 U.S.C. § 112(a), mandates that a patent specification must describe the invention in such clear terms that a person skilled in the art can ascertain that the inventor was in possession of the claimed invention at the time of filing. This is distinct from enablement, which requires the specification to teach how to make and use the invention.
What are "secondary considerations" of non-obviousness?
Secondary considerations, also known as objective indicia of non-obviousness, are evidence that can demonstrate that an invention would not have been obvious to a person of ordinary skill in the art. Examples include commercial success of the patented invention, long-felt but unsolved needs that the invention satisfies, failure of others to achieve similar results, unexpected results, praise by experts, and commercial praise.
What is the potential impact of this litigation on the generic drug market?
The successful invalidation of Lilly's patents could pave the way for Teva to launch a generic version of Trulicity. Generic competition typically leads to a significant decrease in drug prices, making treatments more accessible and increasing market competition. This can result in substantial revenue losses for the branded drug manufacturer and market gains for the generic competitor.
Citations
[1] Complaint for Declaratory Judgment, Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc., No. 1:16-cv-00596 (D. Del. June 15, 2016).
[2] U.S. Patent No. 8,703,870 (filed Nov. 15, 2013).
[3] U.S. Patent No. 9,089,469 (filed May 19, 2014).
[4] Eli Lilly and Company, 2023 Annual Report (Form 10-K).
[5] Court filings and dockets in Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc., No. 1:16-cv-00596 (D. Del.).
